Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A novel, facile, rapid, and precise synchronous spectrofluorimetric method was evolved for the simultaneous estimation of bisoprolol fumarate and ivabradine in dosage forms and biological fluids. The estimation is based on measuring the first derivative of the synchronous fluorescence spectra of ivabradine and bisoprolol fumarate in ethanol at Δλ = 80 nm. The peak amplitudes are measured at 234.4 nm (zero-crossing point of ivabradine) and 244.0 nm (zero-crossing point of bisoprolol fumarate) to simultaneously analyze bisoprolol fumarate and ivabradine, respectively. The spectrofluorimetric method was optimized by investigating different solvent systems, pH values, and surfactants. The proposed method was linear over concentration ranges 30.0-200.0 ng/ml and 30.0-180.0 ng/ml for ivabradine and bisoprolol fumarate, respectively with detection limits of 4.88 and 5.28 ng/ml. The developed method was used for individual assay of the studied compounds in their pharmaceutical dosage forms with high percentage recoveries. Moreover, the method was applied to analyze ivabradine and bisoprolol fumarate in spiked human urine with percentage recoveries of 99.98 ± 1.16 and 99.95 ± 1.96 for ivabradine and bisoprolol fumarate, respectively. The method greenness was also investigated by Analytical GREEnness (AGREE), Analytical Eco-Scale, and Green Analytical Procedure Index (GAPI) metrics, which ensured the ecofriendship of the proposed method.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bio.4337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report.
J Pharm Health Care Sci
September 2025
Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan.
Background: V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are present in approximately 5% of Japanese patients with colorectal cancer (CRC) who receive BRAF-targeted triplet therapy, consisting of encorafenib (a BRAF inhibitor), binimetinib (a mitogen-activated protein kinase inhibitor [MEKi]), and cetuximab. This combination therapy is associated with an increased risk of cardiac dysfunction (CD), primarily attributed to MEKi. However, the detailed clinical course of this adverse event remains unclear.
View Article and Find Full Text PDFTrastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models.
Biomed Pharmacother
August 2025
CNR, Institute of Clinical Physiology, Pisa, Italy. Electronic address:
Pre-existing cardiovascular disease is a recognised risk factor for cardiotoxicity in HER2-targeted therapies such as trastuzumab (TRZ), but few studies have addressed the impact of TRZ and the effects of cardioprotective drugs in pre-existing cardiac issues. This study examines the impact of TRZ-induced cardiotoxicity in pre-existing cardiac conditions and the effects of captopril and bisoprolol in mouse models with varying degrees of cardiac impairment. Adult mice models with and without baseline cardiac dysfunction ̶ healthy mice (WT), transgenic mice with cardiac hyperaldosteronism (AS) and mice with cardiac dysfunction (AS+ISO) ̶ were randomised to receive placebo, TRZ alone (6 mg/kg/week for 4 weeks), or TRZ administered concomitantly with a cardioprotective therapy based on captopril (ACEi, 20 mg/kg) and bisoprolol (BB, 5 mg/kg) (TRZ+ACEi/BB).
View Article and Find Full Text PDFEffects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial.
Br J Clin Pharmacol
August 2025
Faculty of Medical Sciences, State University of Campinas, Brazil.
Aims: This study compares sequential nephron blockade (SNB) and renin-angiotensin system sequential blockade (RASSB) in patients with resistant hypertension (RHTN), evaluating central systolic pressure, arterial stiffness, pulse pressure (PP) and ambulatory blood pressure monitoring (ABPM).
Methods: Seventy-two RHTN patients were randomly assigned to SNB (n = 35, 22 females, 13 males) or RASSB (n = 37, 22 females, 15 males). SNB included multiple diuretics (furosemide, spironolactone, hydrochlorothiazide) to enhance natriuresis and counter intra-renal compensatory mechanisms.
Effects of bisoprolol combined with torasemide on cardiac electrophysiology in patients with acute myocardial infarction and heart failure.
Front Physiol
August 2025
Department of Cardiovascular Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Objective: This paper aims to assess the impact of bisoprolol combined with torasemide on cardiac electrophysiological parameters in acute myocardial infarction (AMI) patients complicated by heart failure (HF).
Methods: A total of 140 AMI-HF patients were randomized to either the control group (bisoprolol alone for 3 months, n = 70) or an experimental group (bisoprolol for 3 months plus torasemide for 2 weeks, n = 70). The corrected QT (QTc) interval, QT dispersion, B-type natriuretic peptide (BNP) levels, left ventricular ejection fraction (LVEF), serum creatinine, serum potassium, New York Heart Association (NYHA) classification, Borg dyspnea score, lower-limb edema resolution, systolic/diastolic blood pressure (SBP/DBP), heart rate (HR), incidence of ventricular arrhythmia (VA) and atrial flutter/fibrillation (AFL/AF), and cardiovascular and all-cause mortality were evaluated.
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
J Am Coll Cardiol
August 2025
Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address:
In the last decade, the U.S. Food and Drug Administration has approved 6 drugs to reduce morbidity or mortality and improve functional capacity in patients with heart failure with reduced ejection fraction (HFrEF) and 3 drugs to reduce morbidity or mortality in patients with heart failure with preserved ejection fraction (HFpEF).
View Article and Find Full Text PDF